Establishing cutoff values for visual amyloid positivity in [18F]flutemetamol PET.

IF 3.1 3区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Yong-Jin Park, So Young Moon, Joon-Kee Yoon, Su-Jin Lee, Young-Sil An
{"title":"Establishing cutoff values for visual amyloid positivity in [<sup>18</sup>F]flutemetamol PET.","authors":"Yong-Jin Park, So Young Moon, Joon-Kee Yoon, Su-Jin Lee, Young-Sil An","doi":"10.1186/s13550-024-01193-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aimed to establish the optimal cutoff values for visual amyloid positivity using standardized uptake value ratios (SUVRs) in [<sup>18</sup>F]flutemetamol (FMM) positron emission tomography (PET) imaging. Given the variability in amyloid assessment, our goal was to determine cutoff values that enhance diagnostic accuracy and assist clinicians in reliably identifying amyloid positivity.</p><p><strong>Results: </strong>The identified cutoff values for visual amyloid positivity were > 1.6 for the cerebellar gray matter, > 1.38 for the whole cerebellum, and > 0.63 for the pons, yielding high sensitivity (95.5%, 94.5%, and 95.8%, respectively) and specificity (91.2%, 94.3%, and 95.2%, respectively).</p><p><strong>Conclusions: </strong>The SUVR cutoff values demonstrated excellent diagnostic performance, supporting their clinical use in assessing visual amyloid positivity in [<sup>18</sup>F]FMM PET imaging.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"1"},"PeriodicalIF":3.1000,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711603/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-024-01193-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Background: This study aimed to establish the optimal cutoff values for visual amyloid positivity using standardized uptake value ratios (SUVRs) in [18F]flutemetamol (FMM) positron emission tomography (PET) imaging. Given the variability in amyloid assessment, our goal was to determine cutoff values that enhance diagnostic accuracy and assist clinicians in reliably identifying amyloid positivity.

Results: The identified cutoff values for visual amyloid positivity were > 1.6 for the cerebellar gray matter, > 1.38 for the whole cerebellum, and > 0.63 for the pons, yielding high sensitivity (95.5%, 94.5%, and 95.8%, respectively) and specificity (91.2%, 94.3%, and 95.2%, respectively).

Conclusions: The SUVR cutoff values demonstrated excellent diagnostic performance, supporting their clinical use in assessing visual amyloid positivity in [18F]FMM PET imaging.

建立[18F]氟替他莫PET视觉淀粉样蛋白阳性的截止值。
背景:本研究旨在利用[18F]氟替他莫(FMM)正电子发射断层扫描(PET)成像中的标准化摄取值比(SUVRs)建立视觉淀粉样蛋白阳性的最佳临界值。鉴于淀粉样蛋白评估的可变性,我们的目标是确定临界值,以提高诊断准确性,并协助临床医生可靠地识别淀粉样蛋白阳性。结果:视觉淀粉样蛋白阳性的识别临界值为:小脑灰质>.6,整个小脑>.38,脑桥>.63,具有较高的敏感性(分别为95.5%、94.5%和95.8%)和特异性(分别为91.2%、94.3%和95.2%)。结论:SUVR截止值具有出色的诊断性能,支持其在评估[18F]FMM PET成像中视觉淀粉样蛋白阳性的临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
EJNMMI Research
EJNMMI Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-
CiteScore
5.90
自引率
3.10%
发文量
72
审稿时长
13 weeks
期刊介绍: EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信